1-3 of 3
Attila Szanto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up

Gilles Salles, Steven I. Park, Tycel J. Phillips, Jennifer E. Amengual, David J Andorsky, Philip Campbell, Pamela McKay, John P. Leonard, Yingxue Chen, Jade Chen, Rajat Bannerji, Apoorva Kapopara, Attila Szanto, Franck Morschhauser
Journal: Blood
Blood (2023) 142 (Supplement 1): 3035.
https://doi.org/10.1182/blood-2023-179910
Published: 2023
Journal Articles

Pharmacokinetics, Drug Interaction, and Exposure-Safety Analyses of Tazemetostat When Co-Administered with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1

Yingxue Chen, Rajat Bannerji, Renli Teng, Attila Szanto, Julien Ogier
Journal: Blood
Blood (2023) 142 (Supplement 1): 6136.
https://doi.org/10.1182/blood-2023-187069
Published: 2023
Journal Articles

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1

Connie Lee Batlevi, Gilles Salles, Steven I. Park, Tycel J. Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John P. Leonard, Manu Sondhi, Yingxue Chen, Pamela L. Slatcher, Richard Lin, Attila Szanto, Sara Abbadi, Franck Morschhauser
Journal: Blood
Blood (2022) 140 (Supplement 1): 2296–2298.
https://doi.org/10.1182/blood-2022-166991
Published: 2022